|
SEARCH
|
Research Papers by Topic
Diagnostics & Epidemiology
Efficacy
Efficacy - Clinical
Efficacy - Subclinical
Maternal Immunity
Safety
Diagnostics & Epidemiology
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Baysinger - IPVS 2010 (view pdf)
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger - AASV 2010 (view pdf)
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Taylor - AASV 2010 (view pdf)
PRRS control: Has it changed post PCV2? - Jones - BI Pre-AASV Health Seminar 2010 (view pdf)
The quagmire of Enzootic Pneumonia: A view from the trenches - Lowe - BI Pre-AASV Health Seminar 2010 (view pdf)
Diagnosing clinical disease and subclinical infections in a vaccinated population - Schwartz - BI Pre-AASV Health Seminar 2010 (view pdf)
Seroprevalence of PCV2 in Canadian swine herds - Cunningham - IPVS 2008 (view pdf)
The impact of seroconversion following vaccination on the efficacy of PCV2 vaccination - Desrosiers - IPVS 2008 (view pdf)
Correlation of serum PCV2 quantitative PCR test results to tissue IHC lesion scores and mortality rates - Diaz - Leman 2007 (view pdf)
PCV2 infection dynamics under field conditions - Diaz - Leman 2008 (view pdf)
Differential diagnosis of wasting and respiratory disease in PCV2 vaccinated populations of pigs - Diaz - Leman 2009 (view pdf)
Use of cross-sectional serum quantitative PCR for profiling PCV2 infection dynamics - Gonzalez - Leman 2007 (view pdf)
A comparison of cross-sectional quantitative PCV2 PCR vs. individual animal quantitative PCV2 PCR and associated necropsy findings in 4 cases - Johnson - Leman 2008 (view pdf)
Test characteristics when verifying Mycoplasma hyopneumoniae status in expected negative herds - Johnson - Leman 2009 (view pdf)
Diagnostic investigation into a reproductive failure associated with porcine parvovirus and porcine circovirus coinfection - McDowell - AASV 2009 (view pdf)
Survey of PMWS impact on Brazilian swine companies - Schwartz - IPVS 2008 (view pdf)
An investigation into increased finishing mortality associated with uncomplicated PCV Type 2 infection: A case report - Wilt - Leman 2007 (view pdf)
Efficacy
Impact of 1- OR 2-dose PCV2 vaccination regimens on wean-to-finish performance - Erlandson - IPVS 2010 (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey - AASV 2010 (view pdf)
Head-to-head comparison of the level of protection and duration of immunity induced by different commercial PCV2 vaccines and an experimental live vaccine in PCV2 viremic pigs - Opriessnig - AASV 2010 (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey - BI Pre-AASV Health Seminar 2010 (view pdf)
From the outside - Diaz - BI Pre-AASV Health Seminar 2010 (view pdf)
FLEX vaccinology - field application of 200 million doses in the U.S. - Holck - BI Pre-AASV Health Seminar 2010 (view pdf)
Comparison of 1 and 2 dose vaccination regimens using three currently licensed
Mycoplasma hyopneumoniae vaccines in pigs - Baysinger - Leman 2008 (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey - Leman 2009 (view pdf)
A case report on the dynamics of PCVAD in a PCV2-vaccinated herd over time - Cline - Leman 2008 (view pdf)
The impact of seroconversion following vaccination on the efficacy of PCV2 vaccination - Desrosiers - IPVS 2008 (view pdf)
Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine - Eichmeyer - AASV 2009 (view pdf)
Efficacy evaluation of a Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer - IPVS 2008 (view pdf)
Efficacy evaluation of a Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer - Leman 2008 (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow - IPVS 2008 (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow - Leman 2008 (view pdf)
Correlation between viral load and performance in PCV2 vaccinated or non-vaccinated pigs - Holck - Leman 2009 (view pdf)
Comparative efficacy of three U.S. commercially available PCV2 vaccines using two-dose protocols in a commercial production system - Kelly - Leman 2009 (view pdf)
Performance of conventional health pigs vaccinated with Ingelvac MycoFLEX® or Suvaxyn® RespiFend - Kolb - Leman 2008 (view pdf)
Comparison and economic evaluation of two PCV2 vaccination programs used in France - Lewandowski - Leman 2009 (view pdf)
Impact of PCV2 viremia in vaccinated and non-vaccinated pigs - Maass - Leman 2009 (view pdf)
Vaccination against PCV2 versus tissue homogenate in finishing phase - Ramirez - Leman 2008 (view pdf)
Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity against M. hyopneumoniae - Piontkowski - Leman 2008 (view pdf)
Efficacy - Clinical
Impact of Ingelvac CircoFLEX® on PCV2 and porcine circovirus associated disease in a wean-to-finish production system - Arnold - AASV 2008 (view pdf)
Impact of PCV2 vaccination for controlling Porcine Circovirus Associated Disease in a wean to finish production system - Arnold - IPVS 2008 (view pdf)
Finishing mortality in a swine production system using different PCV2 vaccination protocols - Cardinal - IPVS 2008 (view pdf)
An economic analysis of vaccinating pigs with Ingelvac CircoFLEX® to control uncomplicated clinical PCVAD - Cline - IPVS 2008 (view pdf)
Efficacy of Ingelvac® CircoFLEX™ in pigs vaccinated at 3 or 6 weeks of age in a PRRS and Mycoplasma hyopneumoniae-negative production system - Cline - Leman 2007 (view pdf)
Results obtained with a novel PCV2 vaccine to protect multiple ages of pigs against PCVAD - Desrosiers - Leman 2007 (view pdf)
PCV2 infection dynamics in vaccinated versus non-vaccinated groups of pigs from 5 farms - Diaz - Leman 2007 (view pdf)
Effects of porcine circovirus type 2 (PCV2) vaccination on mortality and average daily gain - Feldmann - AASV 2008 (view pdf)
The effect of vaccination against PRRSV on quantitative PCV2 PCR results - Genzow - Leman 2007 (view pdf)
Comparative performance of barns of pigs vaccinated or not vaccinated with a one-shot PCV2 vaccine - Gillespie - IPVS 2008 (view pdf)
Vaccination provides superior control of PCV2 and PCVD - Gonzalez - IPVS 2008 (view pdf)
Controlling PCV2 and co-infections to reduce the impact of PCVAD in growing pigs - Jones - Leman 2007 (view pdf)
Comparative performance of barns of pigs vaccinated with Ingelvac CircoFLEX or other PCV2 vaccines - Kolb - Leman 2007 (view pdf)
Evaluation of Ingelvac CircoFLEX® efficacy in PCVAD affected farrow to finish farms in Korea - Lyoo - IPVS 2008 (view pdf)
Effect of PCV2 vaccination on co-infections with porcine reproductive and respiratory syndrome virus and mycoplasma hyorhinis - Mette - IPVS 2008 (view pdf)
Efficacy of a novel one-shot PCV2 vaccine under Japanese field conditions - Miyashita - IPVS 2008 (view pdf)
Efficacy of a novel one-shot PCV2 vaccine in a multi-site production system in Southern Germany - Ritzmann - IPVS 2008 (view pdf)
Efficacy - Subclinical
Efficacy of Ingelvac CircoFLEX® in a herd with subclinical PCVAD - Bretey - Leman 2008 (view pdf)
Biologic and economic benefits of controlling subclinical PCVAD with vaccination - King - AASV 2008 (view pdf)
Effect of PCV2 vaccination on growth performance in a subclinically affected herd - Orveillon - Leman 2008 (view pdf)
Field evaluation of Ingelvac CircoFLEX® on growth performance of pigs in a subclinical PCVAD herd - Verbeck - AASV 2009 (view pdf)
Performance of Ingelvac CircoFLEX® vaccinated pigs in a subclinical PCVAD herd - Young - IPVS 2008 (view pdf)
Maternal Immunity
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger - IPVS 2010 (view pdf)
Profile and agreement of dam and piglet PCV2 IFA titers - Baysinger - IPVS 2010 (view pdf)
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger - Leman 2009 (view pdf)
Efficacy of PCV2 vaccination of pigs, dams, or both on pig performance - Edler - Leman 2008 (view pdf)
Efficacy of Ingelvac CircoFLEX® in face of maternal antibodies in a field trial in France - Grosse Liesner - Leman 2008 (view pdf)
Lack of interference with maternal immunity and reduction of viremia in PCV2 vaccinated pigs - Ritzmann - IPVS 2008 (view pdf)
Safety
An innovative method for quantifying animal behavior responses to various immunization protocols - Bretey - AASV 2009 (view pdf)
Injection site histologic lesions induced by commercial PCV2 piglet vaccines - Christmas - Leman 2007 (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with mycoplasma vaccines - Fangman - IPVS 2008 (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with Mycoplasma hyopneumoniae vaccines - Fangman - Leman 2008 (view pdf)
Pork quality implications of PCV2 vaccines under normal conditions of use - Haas - IPVS 2008 (view pdf)
Comparative safety of PCV2 vaccines under field conditions - Kolb - AASV 2008 (view pdf)
A laboratory evaluation of the comparative injection site tissue reactivity of PCV2 vaccines - Kolb - IPVS 2008 (view pdf)
Suvaxyn and RespiFend are registered trademarks of Fort Dodge Animal Health.
